Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863915 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00863915 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT00863915, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated as a sprinkle on one tablespoonful of applesauce to healthy subjects after a 10-hour overnight fast
Interventions
- DRUG Ramipril10 mg Capsules, single dose
- DRUG Atlace® 10 mg capsules, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863915
The ClinicalTrials.gov registry entry for NCT00863915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramipril10 mg Capsules, single dose is the first listed.
NCT00863915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863915 about?
NCT00863915 is a clinical study titled "A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce". To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated as a...
What is the current status of trial NCT00863915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00863915?
The interventions under investigation include: Ramipril10 mg Capsules, single dose (DRUG), Atlace® 10 mg capsules, single dose (DRUG).
Who is sponsoring clinical trial NCT00863915?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.